Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SEER 
Seer Inc (SEER)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: SEER (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 1 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -45.2% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 116.06M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 3 | Beta 1.58 | 52 Weeks Range 1.58 - 2.62 | Updated Date 08/29/2025 |
52 Weeks Range 1.58 - 2.62 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.36 | Actual -0.33 |
Profitability
Profit Margin - | Operating Margin (TTM) -506.79% |
Management Effectiveness
Return on Assets (TTM) -15.27% | Return on Equity (TTM) -25.25% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -70626142 | Price to Sales(TTM) 7.13 |
Enterprise Value -70626142 | Price to Sales(TTM) 7.13 | ||
Enterprise Value to Revenue 0.11 | Enterprise Value to EBITDA 1.72 | Shares Outstanding 52294400 | Shares Floating 40279247 |
Shares Outstanding 52294400 | Shares Floating 40279247 | ||
Percent Insiders 3.32 | Percent Institutions 65.42 |
Upturn AI SWOT
Seer Inc
Company Overview
History and Background
Seer, Inc. was founded in 2017 and went public in 2020. It focuses on proteomics, aiming to map the proteome at an unprecedented scale to improve disease detection and treatment.
Core Business Areas
- Proteogenomic Solutions: Develops and commercializes products and services centered around its proprietary Proteograph Product Suite, which enables deep, unbiased proteomic profiling.
- Biotech Solutions: Offer platform for biomarker discover and drug discovery.
Leadership and Structure
Omead Ostadan is the CEO. The company operates with a functional organizational structure, with teams dedicated to R&D, product development, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- Proteograph Product Suite: The core platform that enables researchers to deeply profile the proteome. Market share data is currently unavailable. Competitors include Thermo Fisher Scientific, Agilent Technologies, and Bruker Corporation within the broader proteomics space. This product is used in biomarker discovery, drug development, and translational research.
Market Dynamics
Industry Overview
The proteomics market is growing, driven by increasing demand for personalized medicine, biomarker discovery, and drug development. Technological advancements are enabling deeper and more efficient proteomic analysis.
Positioning
Seer is positioned as a technology innovator in the proteomics space, with a focus on enabling comprehensive and unbiased proteomic profiling. It aims to disrupt traditional proteomics workflows with its Nanoparticle technology.
Total Addressable Market (TAM)
The proteomics market is estimated to be in the billions of dollars, with projections for significant growth in the coming years. Seer is positioning itself to capture a substantial share of this growing market by offering a differentiated and high-performance platform.
Upturn SWOT Analysis
Strengths
- Proprietary Nanoparticle Technology
- Strong focus on innovation
- Potential to disrupt proteomics market
- Experienced management team
Weaknesses
- Relatively new company with limited commercial track record
- High operating expenses
- Reliance on a single product suite
- Cash burn
Opportunities
- Expanding applications of proteomics in drug discovery and diagnostics
- Partnerships with pharmaceutical companies and research institutions
- Development of new products and services based on its technology
- Increasing adoption of proteomic technologies in clinical settings
Threats
- Competition from established players in the proteomics market
- Regulatory hurdles for clinical applications
- Technological advancements by competitors
- Economic downturn affecting research funding
Competitors and Market Share
Key Competitors
- TMO
- DHR
- AGIL
Competitive Landscape
Seer possesses advantages due to its novel Nanoparticle technology, allowing in-depth proteomics research. Seer's new to market and must compete against well-funded larger compaines
Growth Trajectory and Initiatives
Historical Growth: Growth trajectory dependent on actual revenue and market penetration.
Future Projections: Future growth projections rely on analyst estimates and company guidance, unavailable in this context.
Recent Initiatives: Recent initiatives focus on expanding the application of the Proteograph platform and establishing partnerships with key players in the life sciences industry.
Summary
Seer is an innovative proteomics company with a disruptive technology and a strong focus on accelerating biomarker discovery. However, the company is still in its early stages of commercialization and faces competition from established players. Successfully scaling production and expanding its customer base will be crucial. Investors should monitor revenue growth, cash burn, and the company's ability to secure partnerships to assess its long-term potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Analyst Reports (Hypothetical)
- Market Research Reports (Hypothetical)
Disclaimers:
This analysis is based on limited information and hypothetical data. It is not financial advice. Conduct thorough research before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Seer Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2020-12-04 | Founder, CEO, & Chair of the Board of Directors Dr. Omid C. Farokhzad M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 134 | Website https://seer.bio |
Full time employees 134 | Website https://seer.bio | ||
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.